{"name": "CureVac",
 "permalink": "curevac",
 "crunchbase_url": "http://www.crunchbase.com/company/curevac",
 "homepage_url": "http://www.curevac.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2000,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@curevac.com",
 "phone_number": "49(0)-70-71-9-20-53-0",
 "description": "",
 "created_at": "Tue Apr 20 07:10:36 UTC 2010",
 "updated_at": "Sun Mar 31 09:42:39 UTC 2013",
 "overview": "\u003Cp\u003ECureVac GmbH is a biopharmaceutical company specializing in the prophylactic and\ntherapeutic  application of  messenger RNA  (mRNA). CureVac\u0026amp;apos;s  lead programme is dedicated  to the development of active  immunotherapies (based on its RNActive\u00c2\u00ae technology) for the treatment of prostate cancer and non-small cell lung cancer. Furthermore, in preclinical studies, CureVac is developing prophylactic vaccines and adjuvants to address infectious diseases.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       56],
      "assets/images/resized/0008/4249/84249v1-max-150x150.jpg"],
     [[178,
       67],
      "assets/images/resized/0008/4249/84249v1-max-250x250.jpg"],
     [[178,
       67],
      "assets/images/resized/0008/4249/84249v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "\u20ac137M",
 "funding_rounds":
  [{"round_code": "b",
    "source_url": "http://www.curevac.com/news_archive.php?uid=12\u0026lang=en",
    "source_description": "New round of financing for CureVac GmbH Euro 22 million for cancer research and treatment",
    "raised_amount": 22000000.0,
    "raised_currency_code": "EUR",
    "funded_year": 2006,
    "funded_month": 1,
    "funded_day": 18,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "DH Capital",
         "permalink": "dh-capital",
         "image":
          {"available_sizes":
            [[[110,
               134],
              "assets/images/resized/0006/1890/61890v2-max-150x150.png"],
             [[110,
               134],
              "assets/images/resized/0006/1890/61890v2-max-250x250.png"],
             [[110,
               134],
              "assets/images/resized/0006/1890/61890v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "OH Beteiligungen",
         "permalink": "oh-beteiligungen",
         "image": null},
       "person": null}]},
   {"round_code": "c",
    "source_url": "http://onbiovc.com/curevac-gmbh-series-c-349m/",
    "source_description": "CureVac, GmbH: Series C $34.9M",
    "raised_amount": 34900000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 5,
    "funded_day": 10,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "dievini Hopp Biotech Holding",
         "permalink": "dievini-hopp-biotech-holding",
         "image":
          {"available_sizes":
            [[[150,
               44],
              "assets/images/resized/0010/1829/101829v1-max-150x150.jpg"],
             [[250,
               73],
              "assets/images/resized/0010/1829/101829v1-max-250x250.jpg"],
             [[284,
               84],
              "assets/images/resized/0010/1829/101829v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "d",
    "source_url": "http://www.prnewswire.com/news-releases/curevac-secures-eur80-million-in-series-d-financing-170137536.html",
    "source_description": "CureVac Secures EUR80 Million in Series D Financing",
    "raised_amount": 80000000.0,
    "raised_currency_code": "EUR",
    "funded_year": 2012,
    "funded_month": 9,
    "funded_day": 18,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "dievini Hopp Biotech Holding",
         "permalink": "dievini-hopp-biotech-holding",
         "image":
          {"available_sizes":
            [[[150,
               44],
              "assets/images/resized/0010/1829/101829v1-max-150x150.jpg"],
             [[250,
               73],
              "assets/images/resized/0010/1829/101829v1-max-250x250.jpg"],
             [[284,
               84],
              "assets/images/resized/0010/1829/101829v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "HQ",
    "address1": "Paul-Ehrlich-Str. 15",
    "address2": "",
    "zip_code": "72076",
    "city": "Tuebingen",
    "state_code": null,
    "country_code": "DEU",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        96],
       "assets/images/resized/0008/4250/84250v1-max-150x150.jpg"],
      [[250,
        161],
       "assets/images/resized/0008/4250/84250v1-max-250x250.jpg"],
      [[450,
        290],
       "assets/images/resized/0008/4250/84250v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}